Results 101 to 110 of about 3,132 (216)
Cost-Effectiveness and Budget Impact Analysis of the Use of Faricimab in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Colombia
Journal of Health Economics and Outcomes Research# Background
Retinal diseases are major contributors to disability, significantly affecting patients' quality of life. Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) represent a significant disease and economic ...Daniel Samacá-Samacá, Antonio Robles, Hugo Ocampo, Francisco J. Rodríguez, Carolina Sardi-Correa, Laura Prieto-Pinto, Christian Bührer, Camilo Tamayo, David Rodríguez, Mauricio Hernández-Quintana +9 moredoaj +1 more sourceFaricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials [PDF]
Purpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with ...Korobelnik Jean-François, Tóth-Molnár Edit, Ives Jane A., Schlottmann Patricio G., Baumal Caroline R., Jaffe Glenn J., Seres András I., Murata Toshinori, Haskova Zdenka, Eter Nicole, Wykoff Charles C., Ruamviboonsuk Paisan, Papp András, Sun Xiaodong, Wong Tien Y., Asik Kemal, Csaky Karl G., Wells John A., Kollaborációs szervezet: YOSEMITE and RHINE Investigators, Silverman David, Hee Yoon Young, Lin Hugh, Tang Yannan +22 morecore +1 more sourceRecurrent uveitic macular edema managed with intravitreal faricimab injection
Journal of Ophthalmic Inflammation and InfectionPurpose To present a case of recurrent uveitic macular edema (UME) treated with intravitreal faricimab injection. Methods Single case report from a tertiary referral center. Observations A 63-year-old Caucasian female presenting with recurrent UME due to Negin Yavari, Dalia El Feky, Frances A. Anover, Khiem Nguyen, Azadeh Mobasserian, Quan Dong Nguyen, Christopher Or +6 moredoaj +1 more sourceEfficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
The Lancet, 2022 C. Wykoff, Francis M. Abreu, A. Adamis, K. Basu, David A. Eichenbaum, Z. Haskova, Hugh Lin, A. Loewenstein, S. Mohan, I. Pearce, T. Sakamoto, P. Schlottmann, David Silverman, Jennifer Sun, J. A. Wells, J. Willis, R. Tadayoni, T. Aaberg, A. Abbey, E.B.K Abdulaeva, Santiago Abengoechea, P. Abraham, T. Ach, S. Adams, A. A. Civera, S. Adrean, H. Agostini, S. Alam, A. Alezzandrini, V. Alfaro, D. Aliseda, A. Almony, P. Amat, Payam Amini, Andrew N. Antoszyk, L. Arias, R. Asaria, Marcos P. Ávila, C. Awh, Joaquín Bafalluy, C. Baker, F. Bandello, M. Barakat, K. Barraza, Gyorgy Bator, C. Baumal, Rubens N. Belfort, C. Bergstrom, George Bertolucci, T. Bochow, M. Bolz, Emilia Borcz, A. Bordon, D. Boyer, Galina Bratko, M. Brent, Jamin S. Brown, David M. Brown, M. Budzinskaya, S. Buffet, S. Burgess, B. Burton, M. Busquets, F. Cabrera, C. Cagini, J. Calzada, P. Campochiaro, John Carlson, A. Castellarin, C. Cava, V. Chaikitmongkol, C. Chan, E. Chang, Jonathan J Chang, Andrew Chang, Steve Charles, N. Chaudhry, C. Chee, Judy Chen, F. Chen, S. Chen, R. Cheong-Leen, A. Chiang, M. Chittum, David Chow, B. Connolly, P. Cornut, K. Csaky, Carl J. Danzig, Arup Das, Vesselin Daskalov, C. Desco, A. Dessouki, J. Dickinson, B. Do, Michael L Dollin, P. Dugel, J. Dusová, David A. Eichenbaum, B. Eldem, R. Engstrom, Jan Ernest, J. Escobar, S. Esposti, N. Eter, N. Falk, A. Farkaš, L. Feiner, N. Feltgen, C. Fernández, Alvaro Fernandez Vega, P. Ferrone, J. Figueira, M. Figueroa, .Oliver Findl, Howard Fine, J. Fortun, G. M. Fox, S. Foxman, C. Framme, S. Fraser-bell, Arthur D. Fu, A. Fukutomi, Nicholas Fung, F. Sola, R. Gallego-Pinazo, Renata Garcia, A. García-Layana, Maciej Gawęcki, S. George, F. Ghanchi, G. Ghorayeb, R. Goldberg, M. Goldstein, Nuno Gomes, Francisco Gomez Ulla, Victor M. Gonzalez, C. Greven, Sunil Gupta, Miguel Guzman, M. Harris, Katja Hatz, Vivienne Hau, V. Hau, Ken Hayashi, J. Heier, E. Herba, Vrinda S. Hershberger, Patrick Higgins, A. Hirakata, A. Ho, N. Holekamp, S. Honda, Jason Hsu, Allen Hu, Maria Hurcikova, Y. Ikeda, R. Isernhagen, Y. Ito, Tim Jackson, R. Jacoby, A. Jafree, G. Javey, Cameron G. Javid, Chirag Jhaveri, Mark Johnson, Marek Kacerík, J. Kałużny, D. Kampik, S. Kang, K. Kapoor, L. Karabas, Tsutomu Kawasaki, Á. Kerényi, A. Khanani, R. Khurana, Brian Kim, Kazuhiro Kimura, Genichiro Kishino, S. Kitano, Kendra Klein-Mascia, G. Kokame, J. Korobelnik, A. Kulikov, Ajay E. Kuriyan, Henry Kwong, R. Kwun, T. Lai, Chi-Chun Lai, Philip G. Laird, L. Lalonde, P. Lanzetta, M. Larsen, C. Laugesen, D. Lavinsky, O. Lebreton, Seong-Cheol Lee, J. Levy, B. Lipkova, Mimin Liu, Judy C. Liu, C. Lohmann, N. London, K. Lorenz, A. Lotery, D. L. Rechy, S. Lujan, P. Ma, T. Maeno, S. Mahmood, Fuad Makkouk, Khurram Malik, D. Marcus, A. Margherio, L. Mastropasqua, R. Maturi, Frank McCabe, M. Mckibbin, H. Mehta, G. Menon, Jale Menteş, K. Michalska-Małecka, A. Misheva, Y. Mitamura, Paul Mitchell, Yasha S. Modi, Q. Mohamed, J. Montero, Jeffrey T. Moore, V. M. Cantón, Haia Morori-Katz, T. Morugova, Tomoaki Murakami, M. Muzyka-Woźniak, M. Nardi, J. Němčanský, Kamila Nester-Ostrowska, Julio Neto, Charles Newell, M. Nicolò, J. Nielsen, K. Noda, A. Obana, N. Ogata, H. Oh, K. Oh, Matthew P. Ohr, P. Oleksy, Scott C. N. Oliver, S. Olivier, James M. Osher, S. Ozcaliskan, B. Ozturk, A. Papp, K. Park, D. Parke, M. Parravano, Sugat S Patel, Sunil S. Patel, I. Pearce, J. Pearlman, F. Penha, I. Perente, S. Perkins, G. Pertile, I. Petkova, T. Peto, D. Pieramici, A. Pollreisz, P. Pongsachareonnont, N. Pozdeyeva, S. Priglinger, J. Qureshi, D. Raczyńska, R. Rajagopalan, J. Estudillo, P. Raskauskas, R. Rathod, H. Razavi, C. Regillo, F. Ricci, S. Rofagha, Dominika Romańczak, B. Romanowska-Dixon, D. Rosberger, I. Rosenblatt, B. Rosenblatt, A. Ross, Paisan Ruamviboonsuk, J. Moreno, G. Salomão, S. Sandhu, D. Sandner, L. Sararols, Osamu Sawada, Ramin Schadlu, P. Schlottmann, C. Schuart, B. Seitz, A. Seres, F. Şermet, S. Shah, Ankur Shah, Rohan Shah, Sumit Sharma, T. Sheidow, V. Sheth, A. Shimouchi, M. Shimura, B. Sikorski, Rufino Silva, M. Singer, L. Singerman, Rishi P. Singh, E. Souied, D. Spinak, G. Spital, N. Steinle, Jeffrey Stern, G. Stoller, R. Stoltz, Cameron Stone, Amy Stone, Eric P Suan, M. Sugimoto, I. Sugita, Jennifer Sun, Xiaodong Sun, I. Suñer, L. Szalczer, Timea Szecsko, A. Tabassian, Hitoshi Takagi, K. Takayama, A. Taleb, J. Talks, G. Tan, T. Tanabe, Stanford E. Taylor, A. Thach, John R. Thompson, Paul S. Tlucek, R. Torti, Daniela Tosheva Guneva, E. Tóth-Molnár, E. Uchiyama, A. Vajas, D. Varma, B. Varsányi, P. Vassileva, S. Vaz-Pereira, M. Veith, J. Vela, F. Viola, G. Virgili, G. Vogt, H. Vorum, Pamela Weber, Thoalf Wecke, R. Wee, M. Weger, P. Weishaar, S. Wickremasinghe, T. R. Williams, Thomas Williams, G. Williams, A. Wolf, J. Wolfe, James Wong, D. Wong, Ian Y. H. Wong, Robert Wong, B. Wowra, E. Wylęgała, Chang-Hao Yang, T. Yasukawa, Paul Yates, G. Yılmaz, Glenn Yiu, Y. Yoon, Barak Yoreh, Shigeo Yoshida, H. Yu, Seung-Young Yu, T. Yurieva, L. Zacharias, K. Zakrzewska, A. Zambrano, B. Zatorska, Carlos Zeolite, J. Zheutlin +390 moresemanticscholar +1 more sourceReal-world use of faricimab to treat DME patients in the UK
Purpose (463 characters)Faricimab, a bispecific antibody inhibiting Angiopoietin-2 (Ang2) and Vascular Endothelial Growth Factor (VEGF)-A, was approved in the UK on May 17, 2022 for the treatment of DME.Shah, Parth, McGrory, Sarah, Gale, Richard P., Lotery, Andrew, De Salvo, Gabriella, Kiire, Christine, Sivaprasad, Sobha, Peto, Tunde, Downey, Louise, Dodds, Melanie, Chi, Gloria, Reynolds, Rhianon, James, Natalee, Downey, Amanda, Pearce, Ian, Talks, James Stephen, Bailey, Clare +16 morecore +1 more sourceSterility of repackaged faricimab for intravitreal administration
Farmacia HospitalariaNew drugs such as faricimab have been developed to treat ophthalmic neovascular diseases. While these drugs increase treatment success, they also increase costs. Repackaging drugs strikes a balance between technical requirements and treatment flexibility.Antonio, Raymundo, Lourdes, Cervera, Francisco, Crespillo, Sara, Esplá, Mariola, Sirvent +4 moreopenaire +2 more sources
